Abstract

Histone deacetylases (HDACs) — enzymes that affect the acetylation status of histones and other important cellular proteins — have been recognized as potentially useful therapeutic targets for a broad range of human disorders. Pharmacological manipulations using small-molecule HDAC inhibitors — which may restore transcriptional balance to neurons, modulate cytoskeletal function, affect immune responses and enhance protein degradation pathways — have been beneficial in various experimental models of brain diseases. Although mounting data predict a therapeutic benefit for HDAC-based therapy, drug discovery and development of clinical candidates face significant challenges. Here, we summarize the current state of development of HDAC therapeutics and their application for the treatment of human brain disorders such as Rubinstein–Taybi syndrome, Rett syndrome, Friedreich's ataxia, Huntington's disease and multiple sclerosis.

Author affiliations

1. Harvard Medical School, Massachusetts General Hospital, Mass General Institute for Neurodegenerative Disease, Building 114-3300, 16th Street Charlestown, Massachusetts 02129-4404, USA.
2. Departments of Psychiatry and Human Behavior, Neurobiology and Behavior, and Biological Chemistry, University of California Irvine, California 92697, USA.

Correspondence to: Aleksey G. Kazantsev¹ Email: akazantsev@partners.org

MORE ARTICLES LIKE THIS

These links to content published by NPG are automatically generated.